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Abstract
The causative bacterium of plague was described and cultured by Alexandre Yersin in Hong Kong in 1894, after which transmission of
bacteria from rodents by ﬂea bites was discovered by Jean-Paul Simond in 1898. Effective treatment with antiserum was initiated in 1896, but
this therapy was supplanted by sulphonamides in the 1930s and by streptomycin starting in 1947. India suffered an estimated 6 million
deaths in 1900–1909, and Vietnam, during its war in 1965–1975, accounted for approximately 80% of the world’s cases; since then, African
countries have dominated, with >90% of the world’s cases in the 1990s and early 21st century. Serological diagnosis with fraction 1 antigen
to detect anti-plague antibodies was developed in the 1950s. Vaccine development started in 1897 with killed whole bacterial cells, and this
was followed by a live attenuated bacterial vaccine, leading to millions of persons receiving injections, but the beneﬁts of these vaccines
remain clouded by controversy. Plasmid-mediated virulence was established in 1981, and this was followed by speciﬁc DNA methods that
have allowed detection of plague genes in skeletal specimens from European graves of the sixth to 17th centuries.
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Introduction
The modern history of plague began in 1894, when Alexandre
Yersin isolated the causative bacterium in culture and identiﬁed
it under the microscope. This event allowed laboratory conﬁr-
mation for accurate diagnoses. There followedmany advances in
treatment and diagnosis, aswell as scientiﬁc understanding of the
disease, which will be reviewed here. Table 1 gives a guide to
some of these historic milestones [1–31].
Discovery of Yersinia pestis as the cause of
Plague: Yersin as the Underdog
Credit for discovering the bacterial cause of plague is accorded
to the French physician Alexandre Yersin (1863–1943), for his
bacteriological investigations in June 1894 inHongKong during a
deadly epidemic [32]. However, credit was not given to Yersin
initially, and nor in the ensuing years by everyone, because he had
a rival in Shibasaburo Kitasato (1851–1935), a Japanese bacte-
riologist sent by his government to investigate the cause of
plague. Rarely in the history of medicine were conditions more
ripe for fruitful investigation of a disease that is now known to
have abundant bacteria in both blood and swollen lymph nodes
(buboes) that are cultivatable and stainable on microscope
slides, as well as readily obtainable in autopsy specimens. Both
scientists were qualiﬁed and had portable laboratory equipment
and supplies with which to solve the mystery of plague’s cause.
Yersin had worked with Emile Roux in Louis Pasteur’s labora-
tories in Paris to characterize diphtheria toxin, and Kitasato had
worked in Robert Koch’s laboratories in Berlin, where he
discovered the bacterial cause of tetanus.
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Yersin was clearly the underdog. Kitasato arrived 3 days
earlier than Yersin, and was accompanied by a team of six
assistants, whereas Yersin had travelled alone from French
Indochina, carrying in his baggage a microscope, sterilizer, and
culture supplies [1]. Kitasato was more senior and famous, and
obtained immediate access to autopsies of plague victims,
whereas Yersin was denied such access for several days. Yersin
was regarded as a small and shy man, spoke no English, and had
an inherent disadvantage, perhaps, of being French in a British
colony. Kitasato got a head start, observing bacteria in the
blood and injecting animals with specimens before Yersin even
arrived. The two rivals were introduced, but they exchanged
little information in their common language of German. The
story was related that, at a meeting of the two during an
autopsy that Kitasato was conducting, Yersin was surprised to
observe that Kitasato was examining blood rather than buboes
[1]. Yersin relayed the suggestion via an intermediary that
buboes should be examined too, with the result that Kitasato
subsequently examined buboes. Both men found bacteria that
they designated as the cause of the disease. Yersin correctly
described his as Gram-negative, whereas Kitasato insisted that
his organism was Gram-positive. Kitasato described his blood
organism as diplococcal and his bubo organism as bacillary,
causing confusion and suggesting to some that his cultures
were contaminated by the pneumococcus. In the ensuing
months and years, Kitasato asserted that his bacillus was
different from that of Yersin [33].
Eventually, against the odds, Yersin took the prize of ﬁnding
the cause of plague. His descriptions were accurate and
consistent. Also, Yersin’s reputation beneﬁted from his links
with colleagues in Paris. During his ﬁrst autopsy in Hong Kong,
he related his method of obtaining ﬂuid from the bubo, seeing
Gram-negative bacilli, injecting animals that he observed to die
with bacteria in their tissues, and sealing a bubo specimen in a
glass tube that was immediately mailed to Paris [2]. These
specimens were received by Albert Calmette and Amedee
Borrel, both destined to be famous for, respectively, a
tuberculosis vaccine and the name of the cause of Lyme
disease, who conﬁrmed Yersin’s ﬁndings and carried out
research with the bacteria to produce a therapeutic antiserum.
In 1895, the last year of Louis Pasteur’s life, Yersin returned to
Paris to collaborate with his associates in Pasteur’s laborato-
ries. Before the end of that year, he was back in Indochina, and
in 1896 he went to Hong Kong again to treat plague victims
with his new antiserum [1].
The name of the organism underwent several changes. It
was Bacterium pestis until 1900, when it changed to Bacillus
pestis. In 1923, it acquired a new designation as Pasteurella
pestis, which it kept up to about 1970, when Yersin obtained
posthumous honour through its ﬁnal name, Yersinia pestis [32].
Role of James Lowson in the Discovery
A hundred years after the discovery of the plague bacillus, the
daughter of James Lowson showed his diary to Yule [34], and
Solomon [35] subsequently carried out historical research by
obtaining further information from Lowson’s granddaughter.
Lowson was a Scottish physician sent by the British Colonial
Medical Service to Hong Kong, where he served as acting
Superintendent of the Civil Hospital, dealing with patient care,
and as Port Medical Ofﬁcer, dealing with quarantine needs.
When plague broke out in Canton in May 1894, Lowson
travelled there to witness fatal cases. When cases appeared in
Hong Kong later in May, he advocated quarantine measures,
established a hospital ship in the harbour for cases, and
persuaded the Governor to initiate disinfection of houses in
affected areas of the city. He was responsible for showing both
Kitasato and Yersin the colony’s facilities for patient care and
diagnosis. He was preferentially hospitable to Kitasato’s team,
dining with them several times, and announcing to the Lancet
by wire on 15 June, the same day on which Yersin arrived, that
Kitasato had succeeded in ﬁnding the cause of plague. Although
Lowson did not befriend Yersin, he spoke to him occasionally,
recording in his diary on 22 June that the ‘Frenchman’ had
found his bacillus. Lowson was aware of the rivalry between
the two scientists, and also of the inaccurate descriptions by
TABLE 1. Modern milestones in the history of plague inves-
tigations
Year Discovery References
1894 Isolation in culture and microscopic description of
causative bacteria
1,2
1898 Flea-borne transmission 3,4
1896 Usefulness of antiserum for therapy 5
1897 First vaccine consisting of heat-killed bacteria
developed and tested
6
1900–1909 Six million deaths in India 7
1931 Live attenuated bacterial vaccine EV developed
and tested
8,9
1937 Usefulness of sulphonamides for therapy 10,11
1939 Formalin-killed bacterial vaccine developed and
tested
12
1940–1947 Large concentrations of blood bacteria correlated
with mortality
13
1947 Usefulness of streptomycin for therapy 13,14
1954 Development of serological tests for diagnosis 15
1965–1975 Vietnam’s ascendancy in incidence 16
1973 Usefulness of trimethoprim–sulphamethoxazole
for therapy
17
1975 Measurement of blood endotoxin correlated with
severity and large concentrations of blood
bacteria
18
1980 Genetic relatedness of Yersinia pestis and Yersinia
pseudotuberculosis
19
1981 Three virulence-associated plasmids in Y. pestis 20–22
1982-present Africa’s ascendancy in incidence 23
1985–1999 Usefulness of gentamicin for therapy 24
1995 Isolation of plasmid-mediated
streptomycin-resistant Y. pestis from patients
25,26
2003 Usefulness of ﬂuoroquinolones for therapy 27
2005–2011 DNA of Y. pestis found in human graves from the
Justinian and medieval eras
28–31
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Kitasato of the organism being Gram-positive and, in blood,
appearing as a diplococcus, but he continued to hold the
opinion that Kitasato deserved credit for ﬁrst ﬁnding the cause
of plague. Solomon speculated that Lowson pushed Kitasato to
hasty and careless publication in order to get the early report
in the Lancet [35].
Yersin’s Observation that Rats were
Infected with the Plague Bacillus
While carrying out his studies of cadavers, Yersin noted many
dead rats in Hong Kong. He examined the lymph glands of
some dead rats, and found the same bacillus that he had
described in human tissues [1,2]. Thus, he was the ﬁrst to
make the important causal connection between rat mortality
and human epidemics. He did not suspect ﬂeas as vectors, but
surmised that rats acquired their infections from contact with
soil, from which he determined that his bacillus could be
cultured [33,35].
Flea-borne transmission
In 1898, Paul-Louis Simond (1858–1947) reported his exper-
iments carried out in Karachi, India [2–4,32]. When ﬂea-in-
fested infected rats were placed into cages separated by wire
mesh from uninfected rats, the uninfected rats acquired fatal
plague infection. Even before his experiments, Simond had
suspected a blood-sucking vector, because he had noted, on
the skin of patients near their buboes, pink nodules, which
contained plague bacilli [2]. Simond additionally observed
bacilli in the stomachs of ﬂeas that had fed on infected rats.
Discovery of Effective Therapies
Antiserum
The ﬁrst application of antiserum to the treatment of patients
is credited to Yersin [5], who used serum developed with the
assistance of his Parisian colleagues Calmette, Roux, and
Borrel. He administered antiserum to 23 Chinese patients in
Hong Kong in 1896, with good results; only two died, giving a
remarkably low mortality rate of 9% [33]. Subsequent uses of
antiserum by Yersin and other workers in this ﬁeld were less
successful, and some efforts were deemed to be failures. The
difﬁculty in evaluating this research stems from the lack of
standardization of batches of serum, which were developed in
different animals in different countries, and administered in
varying doses. Meyer reviewed the literature on antisera [36],
making use of decades of studies in Asia, Africa, and South
America. From a compilation of >20 000 patients, Meyer gave
results for untreated patients and patients who received
antisera. The mortality rate for all patients receiving antiserum
was 35%, whereas untreated patients in these same reports
had a mortality rate of 82%. Although the studies were not
controlled or randomized, the overall impression was that
antiserum therapy was beneﬁcial. The superiority of sulph-
onamides and, later, streptomycin, however, was quickly
appreciated, with the effect that interest in antiserum therapies
declined precipitously during the 1940s.
Sulphonamides
The ﬁrst use of sulphonamides in patients was reported in
1938 in East Africa [10] and in India [11]. In 1937, Carman
described African patients who received intramuscular injec-
tions of the sulphonamide Prontosil. Although only three of six
treated patients survived, the report made a convincing
argument for the drug’s efﬁcacy by comparing these patients
with nine consecutive fatalities in similar patients at the same
hospital before the drug was available. Furthermore, Carman
related how the three deaths occurred in patients who were
treated after 4–5 days of illness, whereas the three surviving
patients had been ill for only 1–3 days after the onset of their
illnesses [10]. Also in 1937, Vine administered Prontosil
injections to three Indian patients with plague. They all
survived, whereas two of four patients not receiving this
treatment died [11]. In 1939 in the Belgian Congo, van Hoof
[37] reported that one of two children treated with sulpha-
nilamide survived. Also in 1939, Chopra et al. [38] reported
that a 6-year-old girl in India was treated successfully with
sulphapyridine. In Madagascar up to early 1940, Girard
reported that 37 patients with bubonic plague received
injections of sulphapyridine (Dagenan), with the result that
only nine, or 24%, died [39]. On the other hand, all eight
patients with pneumonic plague who received the sulphona-
mide died [39]. During an epidemic of plague in 1940 in Egypt,
Kamal et al. [40] reported that sulphanilamide or sulphapyri-
dine was given orally to 81 patients, of whom 27, or, 33% died.
When antiserum was combined with either drug, even better
results were obtained; there were only 12 deaths out of 69
treated patients, or 17% [40]. Subsequent studies in 1943–
1944 in India with sulphadiazine or sulphathiazole demon-
strated that, of 180 patients, only 50, or 28%, died [41]. This
mortality rate was compared with 58% for 165 patients
treated with intravenous iodine, which is considered to be an
ineffective therapy, and who thus constituted a control group.
In cases of pneumonic plague, which advances inexorably to
death within 3 days after the onset of symptoms, attempts to
save patients with sulphonamides were unsuccessful in 1941
[39], but three patients were successfully treated with
sulphapyridine in 1947 in Madagascar [42].
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Streptomycin
The ﬁrst use of streptomycin was reported in 1947 by Videla
[14], who described ﬁve patients with plague in Argentina. All
of them survived, with two being discharged promptly after
therapy, and three having more prolonged hospital courses.
Also in 1947, with reports being published in 1948, patients in
Palestine and India were treated with streptomycin [13,43–48].
In Palestine, Haddad and Valero [43] treated three severely ill
patients who had failed to respond to sulphonamide, with the
result that all survived. In India, Sokhey and Wagle [44]
reported that only four of 118 bubonic plague patients treated
with streptomycin, or 3%, died. These authors updated this
experience in 1953 to include 148 patients, of whom only six,
or 4%, died [45]. In addition to the lower mortality rate with
streptomycin therapy, the authors noted faster defervescence
of patients treated with streptomycin, with an average of 50 h,
as compared with 85–89 h for those treated with sulphadi-
azine or sulphamerazine [45]. One of the authors, Wagle [13],
an astute investigator, performed quantitative blood cultures
to show that three of the fatal cases treated with streptomycin
had high-grade bacteraemia. Wagle called this condition severe
septicaemic plague, indicating that the patients were probably
already in septic shock that was not amenable to reversal with
antibiotic therapy. Also in India, Karamchandi and Rao [46]
described ﬁve patients treated with streptomycin. They all
survived, despite the fact that they were all moribund, and the
condition of three of them had worsened while they were
receiving sulphathiazole during the preceding day. Having been
semiconscious or comatose before treatment, these patients
were observed to regain consciousness, with marked improve-
ment, within 36 h after the start of streptomycin treatment.
These authors updated their experience in the following year
to include 15 moribund plague patients treated with strepto-
mycin, of whom 3, or 20%, died [47]. These physicians were
impressed with both the efﬁcacy of the drug and its superiority
to sulphonamides, because all of their patients were moribund,
and three of the survivors had failed to respond to sulphadi-
azine. Furthermore, all three deaths occurred in patients who
had presented after the third day of illness, with death
occurring during the ﬁrst day of treatment, whereas ﬁve
survivors described in 1948 all presented for treatment after
only 1 day or 2 days of illness [47]. In another report from
India, Datt Gupta related that seven of 24 plague patients
treated with streptomycin, or 29%, died [48]. This relatively
high mortality rate was explained by the study design, whereby
only severe cases were selected to receive streptomycin.
Furthermore, two of the deaths occurred within 12 h after
admission, indicating that the patients probably had advanced
disease before treatment [48]. Thus, 1947 was a watershed
year: all bubonic plague patients fortunate to receive strepto-
mycin within the ﬁrst 2 days of symptoms survived, whereas
deaths were reported only in some ‘moribund’ cases who had
symptoms for at least 3 days or had failed to respond to
sulphonamides [47]. For pneumonic plague, in which sulph-
onamides had failed to save any lives among eight patients in
1941 [39], streptomycin therapy in 1948 in Madagascar was
reported to give recovery in one patient [49], and in 1949 to
give recovery in another two patients [50].
Lack of penicillin efﬁcacy
In the quest for effective therapies, there was general
agreement among investigators that penicillin was useless
[13,36,45,51,52]. Infected mice and guinea pigs failed to
respond to penicillin injections, despite the fact that the
strains of Y. pestis were uniformly susceptible to penicillin, with
sensitivity of 1–5 units/mL [36]. Meyer et al. [36] explained
that penicillin inhibited bacteria well, but much higher
concentrations of drug, approximately 10 000 units/mL, were
required to kill bacteria. Penicillin was also reported to be
without beneﬁt in human plague [13]. This is a peculiar
discrepancy between in vitro susceptibility and clinical perfor-
mance, because other bacteriostatic antibiotics, such as
tetracyclines and chloramphenicol, are effective against plague.
The usual reasons for an antibiotic to fail clinically are
antibiotic resistance in vitro and failure of a drug to penetrate
into infected tissues, neither of which pertained to plague.
Because of this failure of penicillin to show efﬁcacy against
plague, no other b-lactam antibiotic has been tested in humans
with plague, despite experimental efﬁcacy in animal infections
of ampicillin, amoxycillin, and newer cephalosporins [53–55].
Chloramphenicol and oxytetracycline
The ﬁrst applications of chloramphenicol and oxytetracycline
(Terramycin) were reported in Madagascar in 1953 [56].
These antibiotics were as effective as streptomycin, but not
better than streptomycin. Their usefulness was in providing
additional drugs that were available for oral administration in
outpatients. Chloramphenicol had the advantage of good
penetration into cerebrospinal ﬂuid for the rare complication
of plague meningitis. In addition to oxytetracycline and
chlortetracycline, other drugs in this class, including tetracy-
cline and doxycycline, later came into use and have beneﬁted
many patients.
Trimethoprim–sulphamethoxazole
After trimethoprim–sulphamethoxazole was shown to be
active in vitro, as well as effective in experimental animals, Ai
et al. [17] treated 12 patients in Vietnam. All survived, with
defervescence occurring in 2–5 days. Subsequently, in a
prospective randomized comparison with streptomycin, tri-
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methoprim–sulphamethoxazole treatment resulted in the cure
of ﬁve patients, but defervescence was not as prompt as with
streptomycin [18].
Gentamicin
A need arose to ﬁnd a replacement for streptomycin as the
drug of choice, because the manufacturers of streptomycin
discontinued it following reports of toxicity to the kidneys and
ears of patients, as well as to fetuses during pregnancy. In a
retrospective analysis, gentamicin or gentamicin plus tetracy-
cline was administered to 18 patients in the USA between
1985 and 1999, with the excellent result that all survived [24].
Additionally, in a randomized controlled comparison of
gentamicin and doxycycline in Tanzania in 2002, 35 patients
received gentamicin. Only two patients, or 6%, died, both on
the ﬁrst day of treatment [57]. Thus, gentamicin could take the
place of streptomycin as a drug of choice for plague.
Fluoroquinolones
The newest antimicrobial drugs to be employed for plague are
ﬂuoroquinolones. Ciproﬂoxacin and other ﬂuoroquinolones
were effective in animal studies [54,58,59]. Although prospec-
tive comparative studies have not been carried out in humans,
one patient in the USA and ﬁve patients in Algeria were
reported to be successfully treated with ciproﬂoxacin [27,60].
Rarity of antibiotic resistance
Only two persons with plague have ever been reported to be
infected with streptomycin-resistant Y. pestis. Both were in
Madagascar in 1995, and their survival could be attributed to
receiving trimethoprim–sulphamethoxazole concomitantly
with streptomycin [25,26]. Both cases were demonstrated to
be caused by bacteria that harboured resistance plasmids that
were transferable from other bacterial species. Fortunately,
these resistant strains did not persist in the environment,
because all subsequent cases of plague have been caused by
antibiotic-susceptible bacteria [61,62].
A Modern Perspective on Plague Therapies
This history of therapies suggests that antiserum was effective
enough to lower the mortality rate approximately two-fold,
from c. 70% to 35%. Sulphonamides were even better,
reducing mortality rates to approximately 20%, and strepto-
mycin was a breakthrough, reducing it further to approxi-
mately 7%. Streptomycin probably achieved the maximal
antimicrobial beneﬁt, as this has not been improved on with
the currently favoured drugs, gentamicin and doxycycline [57].
The worldwide mortality rate of patients reported to the
WHO in 2000–2009 was actually 7% [63], which could be
lowered further only by patients receiving treatment more
promptly after the onset of their symptoms. For bubonic
plague, treatment started within 3 days after the onset of
symptoms is nearly always effective, whereas, for pneumonic
plague, treatment must be started within 24 h after the onset
of symptoms to be life-saving [56]. None of the studies of
therapeutic efﬁcacy was carried out as a randomized con-
trolled trial, so the results were potentially biased by disease
severity and arbitrary selection criteria. Only in later decades
were objective comparisons of therapies using randomized
designs performed for trimethoprim–sulphamethoxazole vs.
streptomycin and doxycycline vs. gentamicin [18,57].
Fluctuations in Incidence
The WHO estimated that India suffered >6 million deaths
from plague in 1900–1909. This incidence far exceeded that of
any other country, representing a high-water mark for the
disease in the last century, to be followed by stepwise declines
in subsequent decades, reaching <1000 cases a year in 1955
[7,16]. The decline was attributable to public health measures
for rodent control, insecticides, vaccines, and natural cycles in
rodent populations, despite some years with increases in the
1940s, owing to disruptions caused by World War II and the
partition of India [7].
During the war in Vietnam, a breakdown in public health
services and the creation of refugees led to an increase that
peaked at >5000 reported cases a year in 1967 [16]. In 1965–
1975, Vietnam’s 29 003 reported cases accounted for 80% of
the total cases in the world.
Coincident with a reduction in the incidence in Vietnam
after the war, Africa’s reported cases showed increases
starting in 1982, leading to that continent suffering >90% of
the world’s total cases during the 1990s and up to the present
[23]. The countries of Madagascar, Congo and Tanzania
experienced most disease, which was attributed, in part, to
deforestation, urbanization, and civil wars.
Serological Diagnosis
In the 1950s, measurements of antibodies in the blood of
patients as indicators of an immunological response to plague
became possible when serological tests using the fraction 1
antigen of Y. pestis were developed [15]. Previously, a labora-
tory diagnosis of plague had required cultures or observation
with a microscope of bacteria from buboes or blood, but these
specimens and techniques were often unavailable in plague-en-
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demic places. Diagnosis by elevated levels of blood antibodies
or a rise in antibody level between the early and convalescent
phases of disease greatly expanded the numbers of patients
that could be conﬁrmed as having the infection.
Plague Vaccines
The development of vaccines got an early start in 1897, when
Waldemar Haffkine (1860–1930) showed that a heat-killed
culture of plague bacteria protected rabbits against experi-
mental infection. This preparation was tested in humans in
India, with >20 million doses being given, resulting in obser-
vations of reduced incidence and mortality in immunized
persons [6]. In 1931, Georges Girard and Jean Robic
developed a live attenuated non-pigmented strain of the
plague bacillus in Madagascar called EV [9]. This vaccine or
similar live attenuated bacteria with designations including
EV76, EV NIIEG and Tjiwide were administered to millions of
people in Madagascar, Indonesia, Vietnam, and the Soviet
Union [8,64]. In an effort led by Meyer, starting in 1939 [12],
the US Army developed a formalin-killed bacterial cell vaccine
that was given to more than a million American servicemen
deployed to Vietnam. Controversies remain over how much
protection these vaccines provided; besides, all produced local
or systemic reactions that were sometimes serious [65]. By
the end of the 20th century, these vaccines were rarely used
and became commercially unavailable.
Laboratory Correlates of Clinical Severity
and Mortality
Clinical observations of patients had suggested that, after
≥3 days of fever and bubo enlargement, some progressed to
septicaemia and a fatal outcome. In India, Wagle [13] reported
higher mortality rates when patients’ blood cultures grew
>1200 colonies/mL. In Vietnam, measurement of plasma
endotoxin with the sensitive Limulus test showed that patients
with endotoxaemia were severely ill and had greater numbers
of blood bacteria by quantitative culture than patients without
endotoxaemia [18].
Plasmids
The 1980s was the decade in which it was discovered that
extrachromosomal DNA in plasmids was responsible for
virulence. Y. pestis harbours three virulence plasmids—pFra,
encoding the antiphagocytic capsular protein fraction 1 and
the murine toxin that enables bacteria to survive in the ﬂea
gut; pCD (calcium dependency for growth at 37°C), also called
pYV for Yersinia virulence, encoding V antigen and Yersinia
outer proteins, which disrupt phagocytosis and reduce
inﬂammation; and pPla, encoding a plasminogen activator that
allows bacteria to spread in tissues by dissolving ﬁbrin clots
[20–22,66–68]. Earlier genetic studies had hinted at plas-
mid-mediated virulence in Y. pestis. In 1976, Beesley et al. [69]
suggested extrachromosomal inheritance of the virulence
determinants of pesticin, coagulase, and ﬁbrinolytic factor,
and in 1973 Kol’tsova et al. [70] demonstrated that pesticin
could be transmitted as an episome by conjugation from one
bacterial cell to another. The evolutionary implication of
mobile genetic elements determining virulence was that
ancestral progenitor bacteria acquired, from contact with
other donor organisms, their abilities to disseminate by ﬂea
bites and to kill people rapidly. The most likely progenitor of
plague is Yersinia pseudotuberculosis, because this species shares
>90% of its chromosomal DNA sequences with Y. pestis [19].
Although Y. pseudotuberculosis has the pYV plasmid, it must
have acquired both the pFra and pPla plasmids in order to
evolve into our present-day Y. pestis.
Palaeomicrobiology
Three biotypes of Y. pestis—Antigua, Medievalis, and Orien-
talis—are based on glycerol fermentation and nitrate reduc-
tion, and have been postulated to have originated historically in
sequence, with Antigua being the oldest, starting to cause
Justinian plague in the sixth century, Medievalis starting to
cause the Black Death in the 14th century, and Orientalis
originating in southern China in about 1890, spreading along
shipping routes to become the predominant biotype today. By
the use of PCR and known DNA sequences from banks of
DNA from modern Y. pestis strains, it has been possible to
diagnose plague biotypes in the remains of victims from
pandemics in past centuries. The specimen most likely to
harbour intact ancient DNA is dental pulp from teeth
recovered from graves in places known to have suffered
plague mortality. Diagnostic DNA sequences of both plasmids
and the chromosomes were demonstrated in teeth of remains
in London of the 14th century [30,31], remains in France of the
seventh to ninth and 18th centuries [29], and remains in
Germany of the sixth century [28]. These DNA sequences
were nearly identical to modern sequences of genes that
determine virulence, suggesting that ancient strains were
ancestors of today’s bacteria, and that plague’s current status
of relatively subdued endemicity might be attributable to
changes in other genetic features that govern virulence.
Reconstruction of the pPla plasmid from London graves
showed some matches with the Medievalis biotype but not
with the Orientalis biotype, whereas analysis of genes from
graves in France and Germany indicated that ancient strains
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from both the Justinian and medieval eras resembled the
Orientalis biotype [28,29,71]. Further evidence for the
Orientalis biotype came from the ﬁnding of Orientalis-speciﬁc
sequences in these teeth by genotyping, and observation of
deletion of the gene for glycerol dehydrogenase, the enzyme
responsible for glycerol fermentation in the other biotypes
[72,73]. Thus, the previously held notion that ancient
epidemics were caused by the Antigua and Medievalis biotypes
needs to be revised.
Acknowledgements
The author thanks R. Brubaker and J. Levin for reviewing the
manuscript, and M. Lippman for bibliographic assistance.
Transparency Declaration
T. Butler has received research grants from Pﬁzer, Roche,
Chiron, and Abbott. Role of funding source: not applicable
References
1. Solomon T. Alexandre Yersin and the plague bacillus. J Trop Med Hyg
1995; 98: 209–212.
2. Hawgood BJ. Alexandre Yersin (1863–1943): discoverer of the plague
bacillus, explorer and agronomist. J Med Biogr 2008; 16: 167–172.
3. Simond P-L. La propagation de la peste. Ann Inst Pasteur 1898; 12: 625–
687.
4. Gross L. How the plague bacillus and its transmission through ﬂeas
were discovered: reminiscences from my years at the Pasteur Institute
in Paris. Proc Natl Acad Sci USA 1995; 92: 7609–7611.
5. Yersin A. Sur la peste bubonique (serotherapie). Ann Inst Pasteur 1897;
11: 81–93.
6. Hawgood BJ. Waldemar Mordecai Haffkine, CIE (1860–1930): pro-
phylactic vaccination against cholera and bubonic plague in British India.
J Med Biogr 2007; 15: 9–19.
7. Kaul PM. Prevalence of plague in the world in recent years. World
Health Organization. Epidemiological and Vital Statistics Report 1949;
2: 143–162.
8. Demeure C. Live vaccines against plague and pseudotuberculosis. In:
Carniel E, Hinnebusch BJ, eds. Yersinia: systems biology and control.
Wymondham, UK: Caister Academic Press, 2012; 123–142.
9. Coulanges P. Cinquantenaire du vaccine antipesteux EV(Girard et
Robic). Bull Soc Pathol Exot Filiales 1983; 76: 114–120.
10. Carman JA. Prontosil in the treatment of oriental plague. East Afr Med J
1938; 14: 362–366.
11. Vine RS. Plague in the Nilgiris. J R Army Med Corps 1938; 71: 382–395.
12. Cavanaugh DC. K F Meyer’s work on plague. J Infect Dis 1974; 129
(suppl): S10–S12.
13. Wagle PM. Recent advances in the treatment of bubonic plague. Ind J
Med Sci 1948; 2: 489–494.
14. Videla CA. Clinica y tratamiento de la peste. El Dia Medico 1947; 19: 1–6.
15. Chen TH, Meyer KF. Studies on immunization against plague. VII. A
hemagglutination test with the protein fraction of Pasteurella pestis: a
serologic comparison of virulent and avirulent strains with observa-
tions on the structure of the bacterial cells and its relationship to
infection and immunity. J Immunol 1954; 72: 282–298.
16. Dennis DT, Gage KL, Gratz N, Poland JD, Tikhomirov E. Plague manual.
Epidemiology, distribution, surveillance and control. WHO/CDS/EDC/99.2.
Geneva: World Health Organization, 1999.
17. Ai NV, Hanh ND, Dien PV, Le NV. Co-trimoxazole in bubonic plague.
Br Med J 1973; 4: 108–109.
18. Butler T, Levin J, Linh NN, Chau DM, Adickman M, Arnold K. Yersinia
pestis infection in Vietnam. II. Quantitative blood cultures and detection
of endotoxin in the cerebrospinal ﬂuid of patients with meningitis. J
Infect Dis 1976; 133: 493–499.
19. Bercovier H, Mollaret HH, Alonso JM et al. Intra- and interspecies
relatedness of Yesinia pestis by DNA hybridization and its relationship
to Yersinia pseudotuberculosis. Curr Microbiol 1980; 4: 225–229.
20. Ferber DM, Brubaker RR. Plasmids in Yersinia pestis. Infect Immun 1981;
31: 839–841.
21. Portnoy DA, Falkow S. Virulence-associated plasmids in Yersinia
enterocolitica and Yersinia pestis. J Bacteriol 1981; 148: 877–883.
22. Ben-Gurion R, Shafferman A. Essential virulence determinants of
different Yersinia species are carried on a common plasmid. Plasmid
1981; 5: 183–187.
23. Neerinckx S, Bertherat E, Leirs H. Human plague occurrences in
Africa: an overview from 1877 to 2008. Trans R Soc Trop Med Hyg 2010;
104: 97–103.
24. Boulanger LL, Ettestad P, Fogarty JD et al. Gentamicin and tetracyclines
for the treatment of human plague: review of 75 cases in New Mexico,
1985–1999. Clin Infect Dis 2004; 38: 663–669.
25. Galimand M, Guiyole A, Gerbaud G et al. Multidrug resistance in
Yersinia pestis mediated by a transferable plasmid. N Engl J Med 1997;
337: 677–680.
26. Guiyole A, Gerbaud G, Buchrieser C et al. Transferable plasmid-med-
iated resistance to streptomycin in a clinical isolate of Yersinia pestis.
Emerg Infect Dis 2001; 7: 43–48.
27. Kuberski T, Robinson L, Schurgin A. A case of plague successfully
treated with ciproﬂoxacin and sympathetic blockade for treatment of
gangrene. Clin Infect Dis 2003; 36: 521–523.
28. Wiechmann I, Grupe G. Detection of Yersinia pestis DNA in two early
skeletal ﬁnds from Ascheim (Upper Bavaria, 6th century A.D.). Am J
Phys Anthropol 2005; 126: 48–55.
29. Drancourt M, Signoli M, Dang LV et al. Yersinia pestis orientalis in
remains of ancient plague patients. Emerg Infect Dis 2007; 13: 332–333.
30. Bos KI, Schuenemann VJ, Golding GB et al. A draft genome of Yersinia
pestis from victims of the black death. Nature 2011; 478: 506–510.
31. SchuenemannVJ, BosK,DeWitte S et al.Targeted enrichment of ancient
pathogens yielding the pPCP1 plasmid of Yersinia pestis from victims of the
black death. Proc Natl Acad Sci USA 2011; 108: E746–E752.
32. Zietz BP, Dunkelberg H. The history of the plague and research on the
causative agent Yersinia pestis. Int J Hyg Environ Health 2004; 207: 165–178.
33. Bendiner E. Alexandre Yersin: pursuer of plague. Hosp Pract 1989; 24:
121–148.
34. Yule WL. A Scottish doctor’s association with the discovery of the
plague bacillus. Scott Med J 1995; 40: 184–186.
35. Solomon T. Hong Kong, 1894: the role of James A Lowson in the
controversial discovery of the plague bacillus. Lancet 1997; 350: 59–62.
36. Meyer KF, Quan SF, McCrumb FR, Larson A. Effective treatment of
plague. Ann NY Acad Sci 1952; 55: 1228–1274.
37. van Hoof L. Peste. Rapport sur l’hygiene publique au Congo Belge
pendant l’annee 1939. 1939; 14–15.
38. Chopra RN, deMonte AJH, Chatterji BC. A case of plague successfully
treated with sulphapyridine. Ind Med Gaz 1941; 76: 89–90.
39. Girard G. Le traitement de l’infection pesteuse par les corps
sulfamides. Peste experimentale et peste humaine. Bull Soc Path Exot
1941; 34: 43–54.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 202–209
208 Clinical Microbiology and Infection, Volume 20 Number 3, March 2014 CMI
40. Kamal AM, Gayed I, Anwar M. On the epidemiology and treatment of
plague in Egypt. The 1940 epidemic. J Egypt Public Health Assoc 1941; 16:
31–103.
41. Wagle PM. Sulphadiazine in the treatment of bubonic plague. Ind Med
Gazette 1944; 9: 585–589.
42. Favarel R, Carriere M, Chartres A. Guerison de trois cas de peste
pulmonaire primitive par le traitement sulfamide. Bull Soc Path Exot
1948; 41: 515–523.
43. Haddad C, Valero A. Streptomycin in bubonic plague. Br Med J 1948; 1:
1026–1027.
44. Sokhey SS, Wagle PM. Sulphonamides and antibiotics in the treatment
of bubonic plague. Abstr Int Congr Trop Med Mal 1948; 56(4th Congr):
17.
45. Sokhey SS, Wagle PM, Habbu MK. Treatment of bubonic plague with
sulfonamides and antibiotics. Bull World Health Organ 1953; 9: 637–643.
46. Karamchandi PV, Rao KS. Streptomycin in human plague. Lancet 1948;
1: 22.
47. Karamchandani PV, Rao KS. Streptomycin in human plague compared
with other treatments. Lancet 1949; 1: 96–97.
48. Datt Gupta AK. A short note on plague cases treated in Campbell
hospital. Ind Med Gaz 1948; 83: 150–151.
49. Estrade F. Un cas de peste pulmonaire primitive traite and gueri par le
streptomycine. Bull Soc Path Exot 1948; 41: 438.
50. Favarel R, Neel R, Radaody P. Arch L’Institut Pasteur De Tananarive
(Extrait du Rappot Annuel). 1949; 17–20.
51. Meyer KF. Modern therapy of plague. JAMA 1950; 144: 982–985.
52. Mafart B, Brisou P, Bertherat E. Epidemiologie et prise en charge des
epidemies de peste en Mediterranee au cours de la seconde guerre
mondiale. Bull Soc Pathol Exot 2004; 97: 306–310.
53. Butler T. Plague and other Yersinia infections. Merigan T.C. Greenough
W.B New York: Plenum Press, 1983.
54. Bonacorsi SP, Scavizzi MR, Guiyole A, Amouroux JH, Carniel E.
Assessment of a ﬂuoroquinolone, 3 B-lactams,2 aminoglycosides and a
cycline in treatment of murine Yersinia pestis infection. Antimicrob Agents
Chemother 1994; 38: 481–486.
55. Byrne WR, Welkos SL, Pitt ML et al. Antibiotic treatment of
experimental pneumonic plague in mice. Antimicrob Agents Chemother
1998; 42: 675–681.
56. McCrumb FR, Mercier S, Robic J et al. Chloramphenicol and terramy-
cin in the treatment of pneumonic plague. Am J Med 1953; 14: 284–294.
57. Mwengee W, Butler T, Mgema S et al. Treatment of plague with
gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin
Infect Dis 2006; 42: 614–621.
58. Russell P, Eley SM, Bell DL, Manchee RJ, Titball RW. Doxycycline or
ciproﬂoxacin prophylaxis and therapy against experimental Yersinia
pestis infection in mice. J Antimicrob Chemother 1996; 37: 769–774.
59. Steward J, Lever MS, Russell P et al. Efﬁcacy of the latest ﬂuoroqu-
inolones against experimental Yersinia pestis. Int J Antimicrob Agents
2004; 24: 609–612.
60. Raoult D, Mouffok N, Bitam I, Piarroux R, Drancourt M. Plague: history
and contemporary analysis. J Infect 2013; 66: 18–26.
61. Urich SK, Chalcraft L, Schriefer ME, Yockey BM, Petersen JM. Lack of
antimicrobial resistance in Yersinia pestis isolates from 17 countries in
the Americas, Africa, and Asia. Antimicrob Agents Chemother 2012; 56:
555–558.
62. Wagner DM, Runberg J, Vogler AJ et al. No resistance plasmid in
Yersinia pestis, North America. Emerg Infect Dis 2010; 16: 885–886.
63. Butler T. Plague gives surprises in the ﬁrst decade of the 21st century
in the United States and worldwide. Am J Trop Med Hyg 2013; 89: 788–
793.
64. Williamson ED, Oyston PCF. Acellular vaccines against plague. In:
Carniel E, Hinnebusch BJ, eds. Yersinia:systems biology and control.
Wymondham, UK: Caister Academic Press, 2012; 143–168.
65. Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert Opin
Biol Ther 2004; 4: 965–973.
66. Carniel E. Evolution of pathogenic Yersinia, some lights in the dark. Adv
Exp Med Biol 2003; 529: 3–12.
67. Protsenko OA, Anisimov PI, Mozharov OT, Konnov NP, Popov IA.
Detection and characterization of the plasmids of the plague microbe
which determine the synthesis of pesticin 1, fraction 1 antigen, and
‘mouse’ toxin exotoxin (abstract). Genetika 1983; 19: 1081–1090.
68. Sodeinde OA, Goguen JD. Genetic analysis of the 9.5-kilobase
virulence plasmid of Yersinia pestis. Infect Immun 1988; 56: 2743–2748.
69. Beesley ED, Brubaker RR, Janssen WA, Surgalla MJ. Pesticins. III.
Expression of coagulase and mechanism of ﬁbrinolysis. J Bacteriol 1967;
94: 19–26.
70. Kol’tsova EG, Suchkov YG, Lebedeva SA. Transmission of a bacterio-
cinogenic factor in Pasteurella pestis. Genetika 1973; 7: 507–510.
71. Achtman M, Morelli G, Zhu P et al. Microevolution and history of the
plague bacillus, Yersinia pestis. Proc Natl Acad Sci USA 2004; 101: 17837–
17842.
72. Drancourt M, Raoult D. Genotyping Yersinia pestis in historical plague.
Lancet Infect Dis 2011; 11: 894–895.
73. Drancourt M. Finally, plague is plague. Clin Microbiol Infect 2011; 18:
105–106.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 202–209
CMI Butler Yersin’s discovery of the causative bacterium 209
